Ublituximab (Briumvi®)

Reduce direct handling to a minimum and wear appropriate protective clothing **Check which form before administering – SC or IV**		
CAUTION: High Administration Risk Rating		
Form & Storage	Briumvi® Concentrate for solution for infusion Each vial contains ublituximab 150mg in 6mL (25mg/mL)	Refrigerate unopened vials at 2°C - 8°C and protect from light.
Reconstitution	Already in solution Do not shake the vial **Dilute further before administration**	
Compatibility & Stability	Sodium Chloride 0.9%	
Premedication	Administer premedication as charted Allow 60 minutes after discontinuing steroids before starting infusion **Methylprednisolone 100mg/100mL Sodium chloride 0.9% IV over 30 minutes** completed at least 1 hour prior to infusion **Chlorphenamine 10mg IV** at least 30 minutes prior to infusion **Paracetamol 1G PO** at least 30 minutes prior to infusion	
Administration	**IV Infusion**	
	First infusion Add contents of one vial, 6mL (150 mg) to 250 mL fluid – see infusion rate sheets below Duration 4 hours **Second and subsequent infusions** Add contents of 3 vials, 18mL (450 mg) to 250mL – see infusion rate sheets below Duration 1 hour	
Documentation Requirements	Document batch numbers and expiry dates of vials in medical notes.	
Monitoring	Patients should be observed during treatment and monitored for at least one hour after the completion of the first two infusions. Subsequent infusions do not require monitoring post-infusion unless IRR and/or hypersensitivity has been observed. Physicians should inform patients that IRRs can occur up to 24 hours after the infusion.	
Adverse Drug Reactions	**Infusion Related Reactions**: Medicinal products for the treatment of hypersensitivity reactions, e.g. adrenaline, oxygen, antihistamines and corticosteroids should be available for immediate use in the event of an allergic reaction during administration of all infusions.	
Disposal	Dispose of infusion bag and administration set in purple-lidded bin.	
Additional Information	The first dose is administered as a 150 mg intravenous infusion (first infusion), followed by a 450 mg intravenous infusion (second infusion) 2 weeks later. Subsequent doses are administered as a single 450 mg intravenous infusion every 24 weeks.	

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542

	The first subsequent dose of 450 mg should be administered 24 weeks after the first infusion. A minimal interval of 5 months should be maintained between each dose of ublituximab.

Information provided relates to Briumvi® (Neuraxpharm Pharmaceuticals)

Briumvi: Infusion time 4 hours
Day 1 Date:_____First dose 150mg/250ml (Conc. 25mg/ml)

TIME		Rate mL/hr	VTBI (30min)	Temp	B/P	R/R	Pulse	O2 sats	PVAD Checked	Initials
	0-30 min	10mL/hr	5mL							
	30-60 min	20mL/hr	10mL							
	60-120 min	35mL/hr	35mL							
	120-180 min	100mL/hr	100mL							
	180-240 min	100mL/hr	100mL							

Briumvi: Infusion time 1 hour (Second and subsequent infusions)
Date:_____ 450mg/250ml

TIME		RATE	VTBI (30mins)	Temp	B/P	R/R	Pulse	O2 sats	PVAD checked	Initials
	0-30 min	100mL/hr	50mL							
	30-60 min	400mL/hr	200mL							